Natera and Insight to Collaborate on Phase 2 Clinical Trial of INCA33890 for Colorectal Cancer
NTRA Natera Inc
$311.98 -2.62%
View chart & analysis → 
- 1Natera and Insight have signed a clinical collaboration agreement to conduct a Phase 2 study of INCA33890 for colorectal cancer.
- 2This clinical trial will target Stage 2/3 colorectal cancer patients who have completed surgery and adjuvant chemotherapy.
- 3Natera will provide clinical data and real-world evidence, supporting longitudinal monitoring via Signatera for up to 12 months.
So what's the key point?
Natera and Insight have decided to work together on a new treatment study for colorectal cancer patients. Natera will provide the data needed to monitor the status of the cancer during this study.
Source Clinical Trials Arena · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.